Advanced Cell Technology

From Wikipedia, the free encyclopedia

'Advanced Cell Technology, Inc.' (Public, OTC:ACTC)
Type Public
Founded 1994
Headquarters Alameda, CA
Website http://www.advancedcell.com/

[edit] Overview

Advanced Cell Technology, Inc. is a biotechnology company applying human embryonic stem (ES) cell technology in the field of regenerative medicine. The Company’s research programs are divided into three core categories: cellular reprogramming, its reduced complexity program, and stem cell differentiation. On August 23, 2006, the Company announced a technique to generate ES cell lines without destroying the embryo. The Company also published positive data for its retinal pigment epithelium (RPE) cell animal model study and announced a collaboration with the Casey Eye Institute at Oregon Health and Science University to conduct preclinical trials for its RPE program. It expects to file an Investigational New Drug (IND) for its RPE program in the 2007. The Company owns or licenses over 300 patents and patent applications and plans to use its own technology to develop treatments for indications, including dermal injuries, macular degeneration, and blood and cardiovascular diseases.

[edit] Management

William M. Caldwell > Chairman of the Board, Chief Executive Officer

Michael D. West > President, Chief Scientific Officer, Director

Jonathan F. Atzen > Senior Vice President, General Counsel

Ivan Wolkind > Vice President - Finance, Chief Accounting Officer

Robert Lanza > Vice President of Medical and Scientific Development

Robert W. Peabody > Vice President of Grant Administration

[edit] External Links

Retrieved from "http://en.wikipedia.org../../../a/d/v/Advanced_Cell_Technology_8464.html"